Press release
Roche, AstraZeneca Market Share in North America and Europe PEGylated Drugs Market|Key Players: Pfizer, Amgen, Biogen, Novo Nordisk, UCB, Merck KGaA
North America and Europe PEGylated Drugs Market
Increasing R&D investment of biotechnology & pharmaceutical companies to develop enhanced PEGylated drugs for treatment of various chronic diseases along with rising occurrence of chronic ailments in developed regions will propel PEGylated drugs market growth over the forecast period. Major advancements in biologics sector including advances in drug antibody conjugates, and immunotherapies will positively impact market growth. Moreover, rising incidences of chronic ailments and increasing death rates associated with cancer in Canada will propel industry growth. However, the side-effects associated with pegylated drugs along with drug failure will impede PEGylated drugs market growth over the forecast timeframe.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2511
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• Roche
• AstraZeneca
• Pfizer
• Amgen
• Biogen
• Novo Nordisk
• UCB
• Merck KGaA
Cancer segment held over 60% of the overall market share in 2017 due to growing prevalence of the disease creating a demand for the development of effective drugs. Benefits offered by PEGylated drugs such as reduced proteolytic degradation along with minimized immunogenicity leading to enhanced therapeutic efficacy will propel market growth. Increasing areas of applications as well as rising adoption of PEGylated drugs to treat various types of cancer will stimulate business growth. Hepatitis segment size was USD 156 million in 2017 and is anticipated to follow a declining trend over the forecast period. However, increasing focus of industry players to develop pegylated drugs used for the treatment of such chronic conditions will contribute to market growth. For instance, launch of Pegasys drug used for treating Hepatitis C in adult patients will fuel market growth.
To understand the implications of the cancer segment in defining the North America and Europe PEGylated drugs market, in 2015 about 1.3 million or 26% of all deaths in Europe resulted from cancer, making it the second biggest cause of fatalities in the EU. The upsurge in cigarette smoking and pollution along with unhealthy dietary consumption among EU population is expected to increase the frequency cancer and other chronic diseases. Consequently, the advantages of PEGylated drugs in improving treatments has inspired a number of companies in the region to develop bio-conjugated drugs, strengthening the North America and Europe PEGylated drugs industry.
Elaborating on the significance of North America and Europe PEGylated drugs market, a slew of PEGylated drug delivery systems such as Neulasta, Onivyde and PEG intron are employed in various cancer treatments, with additional drugs in the pipeline or pending approvals. For instance, the U.S. Food and Drug Administration (FDA) accepted a biologics license application from Shire PLC, a biotech leader in rare diseases, for Calaspargase Pegol (Cal-PEG) as a component of antineoplastic combination therapy for acute lymphoblastic leukemia (ALL) patients. The development is based on Shire’s research and experience with ONCASPAR (pegaspargase), a first-line treatment for ALL approved in the U.S. According to reports on the efficiency and safety of Cal-PEG, if approved it will permit availability of treatments that have a prolonged shelf life beyond the current PEGylated asparaginase treatment.
The advent of PEGylation to increase the power and life of drug induced therapies can be justified by explaining the impact of acute lymphoblastic leukemia (ALL). ALL is technically a cancer of the white blood cells, which leads to excess lymphoblasts in the blood, bone marrow and other locations in the body. The American Cancer Society estimates that the risk of developing the disease is highest among children below 5 years of age, which declines gradually by the mid-20s and then arises again after the age of 50. Further, ALL accounts for close to 75% of the overall leukemia cases in U.S. children and up to 78% for the children in Europe. As such, the obligation to produce potent medicines for combination therapeutic treatments has driven the North America and Europe PEGylated drugs industry.
Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2511
North America & Europe PEGylated Drugs Market by Disease Indication
o Cancer
o Hepatitis
o Multiple sclerosis
o Gastrointestinal disorders
North America & Europe PEGylated Drugs Market by Type
o Monoclonal antibodies (mAbs)
o Colony stimulating factors
o Interferons
Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Roche, AstraZeneca Market Share in North America and Europe PEGylated Drugs Market|Key Players: Pfizer, Amgen, Biogen, Novo Nordisk, UCB, Merck KGaA here
News-ID: 1621640 • Views: …
More Releases from Global Market Insights, Inc.
Hepatitis B Vaccine Market Set to Surpass $12 Billion by 2034
The global hepatitis B vaccine market is poised for significant expansion over the next decade, fueled by rising liver disease cases, expanded immunization coverage, and advancements in vaccine development. Valued at USD 6.7 billion in 2024, the market is projected to reach USD 7.3 billion in 2025 and surge to USD 12 billion by 2034, reflecting a healthy compound annual growth rate (CAGR) of 5.7%.
A major driver behind this growth…
Rare Sugar Market Top 3 Trends, Covid-19 Outbreak, Factors Driving, Threats, Cha …
Rising awareness regarding health & fitness and the subsequent shift in consumer trends towards low-calorie sweeteners will boost rare sugar market share over the forecast spell. Recent years have marked a steady rise in the prevalence of cardiovascular ailments, diabetes, and obesity, among other chronic conditions, which have triggered a massive change in consumer perceptions towards health.
This in turn has led to a surge in demand for various functional foods…
Global Selenium Yeast Market Industry Assessment, Trends, Competitive Landscape, …
The selenium yeast market is anticipated to register substantial gains on account of rising inclination towards organic additives in animal nutrition, with an aim to improve livestock health and production. Consumers are steadily becoming aware of the downsides associated with using synthetic additives. As a result, they are preferring selenium yeast feed grades over other counterparts to provide balanced nutrition to their livestock.
According to Global Market Insights Inc estimates…
Power Distribution Component Market Share, Size, Trends by 2025 | Leading Key pl …
Global Power Distribution Component Market Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight.
Request a sample of this research report @ https://www.gminsights.com/request-sample/detail/3091
Voltage rating have acted as a standard industry protocol toward the installation of power components reliant on regulatory preference, deployment areas, and the group…
More Releases for PEG
Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.
PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. By…
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm…
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.
Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due…
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition…
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are in…
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…
